RxDoctor Payments Data

William Randall, MD

Family Medicine · Kettering, OHNPI 1851355630

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $31 of the $51 with a category attached, or 60.7%. Pfizer accounts for 76.2% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for family medicine clinicians in OH, where the typical reported total is $402.

$51in general payments, 2019–2025

Across 7 payments — averaging $7.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$39
  • Novo Nordisk$12
$7,478,664in research payments, 2019–2025

Across 590 payments — averaging $12,676 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$4.4M
  • Modernatx, Inc.$1.2M
  • Eli Lilly$932K
  • Genentech, Inc.$235K
  • Novartis$199K
  • AbbVie$183K
  • plus $351K from 11 others

What the payments were for

  • Food & beverage$3161%
  • Gifts$2039%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer6$39
Novo Nordisk1$12

How this compares

$51 in reported general payments places this provider in the 15th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$148,113
Medicare patients
272
Services billed
2,453

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide107$121,631
JardianceEmpagliflozin110$73,545
EliquisApixaban89$69,454
MounjaroTirzepatide36$40,769
TrulicityDulaglutide28$37,719
XareltoRivaroxaban43$35,324
FarxigaDapagliflozin Propanediol27$32,925
JanuviaSitagliptin Phosphate23$22,167
JanumetSitagliptin Phos/Metformin Hcl11$18,397
InvokanaCanagliflozin24$16,347
LinzessLinaclotide14$11,707
MyrbetriqMirabegron12$11,540
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$10,349
Lantus SolostarInsulin Glargine,hum.Rec.Anlog39$6,943
NexiumEsomeprazole Magnesium11$6,500

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$12$121,631107 claims
PfizerEliquis, Paxlovid$39$70,801101 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Kettering

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →